Patent US4191748A successfully refreshed from Google Patents.
US4191748A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Novel medicinal composition, especially for the treatment of cellulitis
Assignee: Individual
•
Filing: 1978-01-24
•
Granted: 1980-03-04
•
Expires: 1998-01-24
Abstract
Abstract The composition results essentially from the combination of a phosphodiesterase inhibitor and a fluorinated compound. Preferably it comprises theophylline, thiomucase or hyaluronidase, and sodium fluoride, in dosage unit form for topical, injection or ionization local administration.
Inventors
- 👤 David Holzmann
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-07 09:47
CPC Classifications
A; A61; A61K; A61K8/00; A61K8/18; A61K8/19; A61K8/20; A61K8/21; A61K33/00; A61K33/16; A61K38/00; A61K38/16; A61K38/43; A61K38/51; A61K8/30; A61K8/49; A61K8/494; A61K8/4953; A61K8/64; A61K8/66; A61Q; A61Q19/00; A61Q19/06
Claims Analysis
Total Claims: 11
Claim 1
Independent Claim
57 words
A medicinal composition useful for treating cellulitis, said composition consisting essentially of a xanthic base as a phosphodiesterase inhibitor and a fluorinated compound selected from the group consisting of an alkali metal fluoride, alkaline earth metal fluoride and ammonium fluoride, the inhibitor being present in about 0.1 to 60% by weight of the inhibitor plus fluorinated compound.
Claim 2
Dependent Claim
57 words
A medicinal composition useful for treating cellulitis, said composition consisting essentially of a xanthic base as a phosphodiesterase inhibitor and a fluorinated compound selected from the group consisting of an alkali metal fluoride, alkaline earth metal fluoride and ammonium fluoride, the inhibitor being present in about 0.1 to 60% by weight of the inhibitor plus fluorinated compound.
Claim 3
Dependent Claim
18 words
Medicinal composition according to claim 1, wherein said xanthic base is theophylline or caffeine, alone or in admixture.
Claim 4
Dependent Claim
16 words
Composition according to claim 1, in the form of dosage units containing the inhibitor/fluorinated compound association.
Claim 5
Dependent Claim
21 words
Composition according to claim 1, containing in addition a depolymerization enzyme selected from the group consisting of thiomucase, α-mucase and hyaluronidase.
Claim 6
Dependent Claim
26 words
Composition according to claim 1, in a form suitable for local administration externally and selected from the group consisting of a pomade, ointment, gel and cream.
Claim 7
Dependent Claim
24 words
Composition according to claim 1, in the form of dosage units providing concentrations of fluorine ions of the order of 5 to 10 millimoles/liter.
Claim 8
Dependent Claim
33 words
Composition according to claim 4, in the form of injectable ampoules containing per ml of solution: (1) thiomucase: 100 TRU or hyaluronidase: 500 IU; (2) theophylline: 30 mg; (3) sodium fluoride: 0.5 mg.
Claim 9
Dependent Claim
18 words
Method of treating cellulitis in humans or animals, said method comprising administering a composition according to claim 1.
Claim 10
Dependent Claim
14 words
Composition according to claim 1, in the form of a solution suitable for injection.
Claim 11
Dependent Claim
31 words
Method of treating cellulitis in humans or animals, said method comprising injecting about twice weekly for about 6 to 8 weeks about 4 ml of a solution according to claim 7.
References Cited (Backward Citations)
US2976212A
Cited
US3978213A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1983-03-04 | 1983-09-03 | 1984-03-04 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1987-03-04 | 1987-09-03 | 1988-03-04 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1991-03-04 | 1991-09-03 | 1992-03-04 | $7700.00 | Window Closed / Lapsed |